TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04104217

Intervention type: BEHAVIORAL
Intervention: Music therapy
Description: Music therapy sessions may last 20-60 minutes, with length and frequency to be determined mutually (generally 1-3 times per week). Music therapy sessions are done at the patient's bedside, where the music therapist plays live music on a guitar, keyboard, harp, or percussion instrument, sometimes as accompaniment to singing.

Intervention type: BEHAVIORAL
Intervention: Music therapy
Description: Music therapy sessions may last 20-60 minutes, with length and frequency to be determined mutually (generally 1-3 times per week). Music therapy sessions are done at the patient's bedside, where the music therapist plays live music on a guitar, keyboard, harp, or percussion instrument, sometimes as accompaniment to singing.

Intervention type: BEHAVIORAL
Intervention: Music therapy
Description: Music therapy sessions may last 20-60 minutes, with length and frequency to be determined mutually (generally 1-3 times per week). Music therapy sessions are done at the patient's bedside, where the music therapist plays live music on a guitar, keyboard, harp, or percussion instrument, sometimes as accompaniment to singing.

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Each interview will be conducted in person in a private setting (with the exception of caregivers, who have the option to conduct interviews over the phone if it is not feasible to take place in the hospital). Each interview will follow a semi-structured interview guide and will ask for consent to audio record the interviews .

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Each interview will be conducted in person in a private setting (with the exception of caregivers, who have the option to conduct interviews over the phone if it is not feasible to take place in the hospital). Each interview will follow a semi-structured interview guide and will ask for consent to audio record the interviews .

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Each interview will be conducted in person in a private setting (with the exception of caregivers, who have the option to conduct interviews over the phone if it is not feasible to take place in the hospital). Each interview will follow a semi-structured interview guide and will ask for consent to audio record the interviews .

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Each interview will be conducted in person in a private setting (with the exception of caregivers, who have the option to conduct interviews over the phone if it is not feasible to take place in the hospital). Each interview will follow a semi-structured interview guide and will ask for consent to audio record the interviews .
Study: NCT04306250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apical prolapse fixation - anterior access
Description: The surgery is done in anterior access

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apical prolapse fixation - posterior access
Description: The surgery is done in posterior access
Study: NCT02954185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WellClub

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Study: NCT00741091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid WALLSTENT Monorail Endoprosthesis
Description: A carotid artery stent for use in subjects at high risk for adverse events from Carotid endarterectomy (CEA) due to either anatomic or comorbid conditions who require carotid revascularization in the treatment of ipsilateral or bilateral carotid artery disease.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FilterWire EZ™ System™
Description: Embolic protection device used in conjunction with the Carotid WALLSTENT Endoprosthesis.
Study: NCT01534780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic ventral herniotomy
Description: Laparoscopy in general anesthesia are performed with placement of Physiomesh intraperitoneally. Fixation of the mesh is performed with 1 of 3 possible devices

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic ventral herniotomy
Description: Laparoscopy in general anesthesia are performed with placement of Physiomesh intraperitoneally. Fixation of the mesh is performed with 1 of 3 possible devices

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic ventral herniotomy
Description: Laparoscopy in general anesthesia are performed with placement of Physiomesh intraperitoneally. Fixation of the mesh is performed with 1 of 3 possible devices

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protack
Description: fixation of mesh with protack

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Securestrap
Description: fixation of mesh with Securestrap
Study: NCT01608958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 10 IU oxytocin in 500 ml infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 10 IU oxytocin IM injection
Study: NCT03383029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iEAT Program
Description: The iEAT Program is a six-month long behavioral intervention consisting of 10 biweekly outpatient appointments of about 1 hour in length. The iEAT manual will guide behavioral intervention targeting severe feeding disorders and will involve some combination of escape extinction, reinforcement, and antecedent manipulation of food presentation to lessen the aversive quality of the meal.
Study: NCT01906645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Transitions Innovation (C-TraIn)
Description: Multi-component transitional care intervention including transitional nursing care, pharmacy care, and medical home linkages
Study: NCT01046071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transversus abdominis plane block
Description: UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP block placebo
Description: UL-guided TAP block with 20 ml of saline bilaterally, single dose.
Study: NCT03459521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fendrix or HBVAXPRO 40
Description: To administer hepatitis B virus vaccines in patients with chronic liver disease that have not been previously vaccinated.
Study: NCT04086719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration of tablet BMS- 986165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Oral administration of Pyrimethamine in combination with BMS-986185
Study: NCT04491006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-1017
Description: Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-1017
Description: Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
Study: NCT04448925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inertial-load exercise (ILE)
Description: Length of time between exercise bouts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inertial-load exercise (ILE)
Description: Length of time between exercise bouts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inertial-load exercise (ILE)
Description: Length of time between exercise bouts
Study: NCT01295788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simultaneous RT-CGM and Pump Initiation
Description: Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Initiation of RT-CGM
Description: Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.
Study: NCT00639964

Intervention type: OTHER
Group type: OTHER
Intervention: blood tests
Description: 3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord

Intervention type: OTHER
Group type: OTHER
Intervention: blood tests
Description: 3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord

Intervention type: OTHER
Group type: OTHER
Intervention: blood tests
Description: 3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord

Intervention type: OTHER
Group type: OTHER
Intervention: diet questionnaire
Description: questions about nutrition before and during pregnancy

Intervention type: OTHER
Group type: OTHER
Intervention: diet questionnaire
Description: questions about nutrition before and during pregnancy

Intervention type: OTHER
Group type: OTHER
Intervention: diet questionnaire
Description: questions about nutrition before and during pregnancy

Intervention type: OTHER
Group type: OTHER
Intervention: umbilical cord blood collect
Description: collected at the delivery

Intervention type: OTHER
Group type: OTHER
Intervention: umbilical cord blood collect
Description: collected at the delivery

Intervention type: OTHER
Group type: OTHER
Intervention: umbilical cord blood collect
Description: collected at the delivery

Intervention type: OTHER
Group type: OTHER
Intervention: placenta collect
Description: collected at the delivery

Intervention type: OTHER
Group type: OTHER
Intervention: placenta collect
Description: collected at the delivery

Intervention type: OTHER
Group type: OTHER
Intervention: placenta collect
Description: collected at the delivery
Study: NCT03193216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alginates
Description: Liquid Alginate therapy will be added to twice daily PPI regimen. Patients will be asked to take the alginate solution four times daily (following meals and at bedtime) at 10ml/dose.
Study: NCT01724047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playground Intervention
Description: Intervention is designed for children diagnosed with an autism spectrum disorder (ASD) included in a regular education k through fifth grade classroom for at least 50% of the school day. Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. This study will take place at school. All intervention activities will be conducted during recess or lunch where children with autism may have the most difficulty interacting with peers. A total of 14-16 intervention sessions will be held with the child with autism, school personnel, and the child's classmates. The intervention will last approximately 3 months with a 3-month follow-up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAT Intervention
Description: This study will track the behavioral progress of children whose teachers receive training in these instructional methods. This study also will examine the ability and willingness of teachers to use these methods as they were designed. The study will last approximately 18 weeks (6 weeks of intervention, and a 3 month follow up visit). This study will take place at school. Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. All intervention activities will be conducted with a teacher during the school day but not during instructional time. Study staff will visit the school on a weekly basis to train your child's teacher on evidence-based strategies for teaching children with autism.
Study: NCT03228654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unipolar Electrocautery sealing of vessels
Description: 1. Vaginal walls are incised by monoplar current (40 W)~2. A curved Bulldog Clamp is applied just 0.5 cm lateral to the uterine border along its attachements all through the pedicles. Then unipolar electrocautery (40 W) is applied to the pedicles along the lateral border of the uterus medial to the artery with maximum thickness 1 cm.~3. uterine vessels are individually secured.~4. Conventional volume reduction maneuvers are used as associated procedures in cases of large uteri to create the parauterine space to approach the lateral attachements.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Purohit technique for vaginal hysterectomy
Description: using Bipolar electrosurgical sealing of vessels during vaginal hysterctomy
Study: NCT03976778

Intervention type: OTHER
Group type: OTHER
Intervention: Training program for family physicians on well-child care for children under-5 years
Description: The researchers designed this intervention, which consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
Study: NCT00168714

Intervention type: DRUG
Intervention: BG9418 (interferon beta-1a)
Description: Exposure to Avonex during pregnancy
Study: NCT02652715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salvia hispanica Seed
Description: Given PO
Study: NCT02370199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 670 nm light
Description: 670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octafluropropane
Description: Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
Study: NCT00926952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylaminolevulinate (Metvix, Metvixia)
Description: 2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (Aktilite)
Description: Device set to 37 J/cm². Red light wavelength is approximately 630 nm.
Study: NCT03722797

Intervention type: PROCEDURE
Intervention: Metabolic Cost Testing Procedures
Description: The Oxycon Mobile™Portable VO2 Measurement system will be used to measure VO2 uptake during 2 walking tests. Test order will be randomized.~Treadmill Test: Participants will walk on a treadmill at constant speed, based on the participant's self-selected gait speed, for 2.5 minutes in each stage. Walking will occur at 75% of self-selected gait speed in stage 1, 100% in stage 2, and 125% in stage 3.~Over-ground Test: Participants will walk in an uncarpeted corridor on a course consisting of 2 cones, 20-meters apart. Participants will be instructed to walk at a constant speed for 2.5 minutes in each stage. Instructions will be to walk at their slow speed in stage 1, their usual, comfortable speed in stage 2, and their brisk speed in stage 3.

Intervention type: PROCEDURE
Intervention: Metabolic Cost Testing Procedures
Description: The Oxycon Mobile™Portable VO2 Measurement system will be used to measure VO2 uptake during 2 walking tests. Test order will be randomized.~Treadmill Test: Participants will walk on a treadmill at constant speed, based on the participant's self-selected gait speed, for 2.5 minutes in each stage. Walking will occur at 75% of self-selected gait speed in stage 1, 100% in stage 2, and 125% in stage 3.~Over-ground Test: Participants will walk in an uncarpeted corridor on a course consisting of 2 cones, 20-meters apart. Participants will be instructed to walk at a constant speed for 2.5 minutes in each stage. Instructions will be to walk at their slow speed in stage 1, their usual, comfortable speed in stage 2, and their brisk speed in stage 3.
Study: NCT02107729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Large needle gauge lidocaine injection
Description: 21 G

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Large needle gauge lidocaine injection
Description: 21 G

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Large needle gauge lidocaine injection
Description: 21 G

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal needle gauge lidocaine injection
Description: 23 G

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal needle gauge lidocaine injection
Description: 23 G

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal needle gauge lidocaine injection
Description: 23 G

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small needle gauge lidocaine injection
Description: 27 G

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small needle gauge lidocaine injection
Description: 27 G

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small needle gauge lidocaine injection
Description: 27 G
Study: NCT02434523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this arm will receive pills composed of only Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
Study: NCT00583050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair
Description: Endovascular exclusion of aneurysm
Study: NCT02915354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs could be continued if maintained at a stable dose for at least 4 weeks.
Study: NCT01333137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine and Carboplatin
Description: Gemcitabine 1000 mg/m2/day on Days 1 \& 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P276-00 along with Gemcitabine and carboplatin
Description: In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 \& 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
Study: NCT01939405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: built environment use counseling
Study: NCT02753764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD7624

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD7624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: oral prednisone 20 mg bid for one week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone
Description: oral prednisone 20 mg bid for one week

Intervention type: DRUG
Group type: OTHER
Intervention: prednisone
Description: oral prednisone 20 mg bid for one week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04177628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision making supported by an in-consultation patient decision aid
Description: After having received training in SDM, the doctor will practice SDM supported by an in-consultation PtDA during the consultation with the participant.
Study: NCT02347969

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: X34
Description: Dietary supplement named X34
Study: NCT03650361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene Gel 0.3%
Description: Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Differin 0.3% Topical Gel
Description: Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adapalene Gel 0.3% Vehicle Placebo
Description: Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
Study: NCT00953342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 12 weeks of supervised exercise, 3 x week, 1 hour sessions
Study: NCT01534780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glubran
Description: fixation of mesh with Glubran
Study: NCT02750605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB
Description: Intervention with drug eluting balloon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA
Description: Intervention with old technology as comparison
Study: NCT01619020

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed Lignans
Description: We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flaxseed Lignans
Description: We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.